188 related articles for article (PubMed ID: 14713258)
1. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut.
Ardill JE; Erikkson B
Endocr Relat Cancer; 2003 Dec; 10(4):459-62. PubMed ID: 14713258
[TBL] [Abstract][Full Text] [Related]
2. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.
Stridsberg M; Oberg K; Li Q; Engström U; Lundqvist G
J Endocrinol; 1995 Jan; 144(1):49-59. PubMed ID: 7891024
[TBL] [Abstract][Full Text] [Related]
3. [Significance of biochemical markers in the diagnosis of neuroendocrine tumours and for the follow-up of patients].
Tőke J; Czirják G; Tóth M; Rácz K; Patócs A
Orv Hetil; 2014 Nov; 155(45):1775-82. PubMed ID: 25362640
[TBL] [Abstract][Full Text] [Related]
4. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours.
Oberg K
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S17-25. PubMed ID: 22005113
[No Abstract] [Full Text] [Related]
5. Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors.
Eriksson B; Oberg K
Acta Oncol; 1991; 30(4):477-83. PubMed ID: 1854505
[TBL] [Abstract][Full Text] [Related]
6. Raised circulating Neurokinin A predicts prognosis in metastatic small bowel neuroendocrine tumours. Lowering Neurokinin A indicates improved prognosis.
Ardill JE; McCance DR; Stronge WV; Johnston BT
Ann Clin Biochem; 2016 Mar; 53(Pt 2):259-64. PubMed ID: 26038607
[TBL] [Abstract][Full Text] [Related]
7. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators.
Ardill JE; O'Dorisio TM
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):777-90. PubMed ID: 21095544
[TBL] [Abstract][Full Text] [Related]
8. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.
Panzuto F; Severi C; Cannizzaro R; Falconi M; Angeletti S; Pasquali A; Corleto VD; Annibale B; Buonadonna A; Pederzoli P; Delle Fave G
J Endocrinol Invest; 2004 Jan; 27(1):6-11. PubMed ID: 15053236
[TBL] [Abstract][Full Text] [Related]
9. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
Singh S; Law C
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
[TBL] [Abstract][Full Text] [Related]
10. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
11. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
[TBL] [Abstract][Full Text] [Related]
12. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
[TBL] [Abstract][Full Text] [Related]
13. Tumour markers in neuroendocrine tumours.
Oberg K; Janson ET; Eriksson B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S160-2. PubMed ID: 10604122
[TBL] [Abstract][Full Text] [Related]
14. Chromogranin A: its clinical value as marker of neuroendocrine tumours.
Nobels FR; Kwekkeboom DJ; Bouillon R; Lamberts SW
Eur J Clin Invest; 1998 Jun; 28(6):431-40. PubMed ID: 9693933
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute.
Jun E; Kim SC; Song KB; Hwang DW; Lee JH; Shin SH; Hong SM; Park KM; Lee YJ
Surgery; 2017 Jul; 162(1):120-130. PubMed ID: 28262254
[TBL] [Abstract][Full Text] [Related]
16. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
18. A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours.
Eriksson B; Arnberg H; Oberg K; Hellman U; Lundqvist G; Wernstedt C; Wilander E
Acta Endocrinol (Copenh); 1990 Feb; 122(2):145-55. PubMed ID: 2316306
[TBL] [Abstract][Full Text] [Related]
19. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
20. Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.
Rogowski W; Wachuła E; Lewczuk A; Kolasińska-Ćwikła A; Iżycka-Świeszewska E; Sulżyc-Bielicka V; Ćwikła JB
Future Oncol; 2017 May; 13(12):1069-1079. PubMed ID: 28095720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
